Improved survival in women with BRCA-associated ovarian carcinoma.
about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesBRCAness: finding the Achilles heel in ovarian cancerThe role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancerMolecular tumor profiling: translating genomic insights into clinical advancesTP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.Emerging and Evolving Ovarian Cancer Animal ModelsOlaparib in the management of ovarian cancerFine tuning chemotherapy to match BRCA1 statusAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancerEvolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancersPARP inhibitor treatment in ovarian and breast cancerInvestigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group StudyMolecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesPotential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the TumorThe preclinical natural history of serous ovarian cancer: defining the target for early detectionThe role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.Prognostic biomarkers in ovarian cancer.Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888.BRCAness profile of sporadic ovarian cancer predicts disease recurrence.BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.Oncogenes and tumor suppressor genesAssociation of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancerBRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcomeClinical management of BRCA1 and BRCA2 mutation carriers.A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapyPrevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.
P2860
Q21129302-60B0C47C-A7C1-4EED-BFF8-A98EE98B4E49Q24630872-A8132979-9438-40FB-B54F-C119985A2860Q24791520-36120FD0-1CD0-4DCE-84CC-61E654AD8B3EQ24797250-45222E9A-3F09-4A82-BA65-8063771A5BBBQ24812743-ABB7D777-F533-4DD5-B0DE-F884C6BC0C97Q26783909-F546C3B1-A89B-4B26-8E90-C58483862EF6Q26797166-278FD584-3C48-4B46-B717-C00A5CED7845Q27694529-6FA1DE79-D60C-4EEE-AE0D-A2FA65D6E1ABQ27851709-53B3AC85-8ED0-4425-BB6B-7C60E6C5F7B0Q28538059-0C7E1334-074F-4816-8D5C-66E122A990F0Q28542563-942DB909-9AF3-47BE-82A1-822345787076Q28741688-0F5F9802-4E2F-4D14-87F5-BFF706A4EDD5Q30277784-9D05F77A-AC00-4D59-BADE-39C5BEAE14FAQ30417640-3A1A966E-B248-4259-BF0E-ED37F0701829Q30448232-CF90C006-D842-4379-8DE6-3356FDF38CB7Q33258367-F7024B72-B4C0-4265-A637-F8CCB79557FDQ33315604-69CB1E87-1724-4F93-96FD-8E8FE48582D7Q33416772-D4C64418-2D8D-4F31-B3F5-6092CC65EC26Q33458308-6BAE17E9-1A99-49F3-823C-F37461690023Q33487678-644AC1E6-E883-4FF8-AA8F-45013C3C852BQ33553318-C0CE3CD9-64A7-4402-B6B4-4C60CC41F9B3Q33598001-0D58F131-2CFB-4FB3-B0B5-55BE6D5C11BAQ33798999-FB77A43C-F013-4F0E-8889-1561E2879585Q33889555-CC4E8A97-E07E-498B-B4B3-1E8872E51E89Q33944203-C0183BE9-6159-4AB4-A459-7AD9EAF06BD8Q33965570-FFA4C640-8100-4D7D-B575-14351B7C818AQ34049228-D06953A6-C5D7-40D9-8E68-0F76EA8B57FEQ34049234-2594A13F-53A6-4D1C-92FA-57CDF06CD7F7Q34086636-5DFD9296-0AC6-4BC5-A6FA-1B58AAD48E69Q34092001-F2DA92D5-E682-42B0-9346-B6BD20347F6AQ34130956-629357AF-895E-4B1B-B7D8-CCDA77E986D8Q34134454-DD9AAE1F-EF62-46C4-9582-BBD4C33FB0F8Q34149922-CBD1AF55-59A2-47DE-823A-E80D6F9B9685Q34155131-8F931925-6F52-45BB-89D9-F38038DEA1F2Q34252163-E025DF51-0A60-4013-8AEE-382CB0A9051CQ34305493-DB7307D5-30E0-41D6-B1BE-0E9F25C3F6B8Q34381630-A522A76F-9DE1-4BA8-B35B-55544E838D24Q34568554-C7D4B5E5-B0A3-4687-8543-04BA9A6982A0Q34599539-45CFF2F8-74AD-45AB-8FBD-B9B2ED93B626Q34639149-D9E2854A-BF1C-4554-B27F-1995BA70F462
P2860
Improved survival in women with BRCA-associated ovarian carcinoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Improved survival in women with BRCA-associated ovarian carcinoma.
@en
Improved survival in women with BRCA-associated ovarian carcinoma.
@nl
type
label
Improved survival in women with BRCA-associated ovarian carcinoma.
@en
Improved survival in women with BRCA-associated ovarian carcinoma.
@nl
prefLabel
Improved survival in women with BRCA-associated ovarian carcinoma.
@en
Improved survival in women with BRCA-associated ovarian carcinoma.
@nl
P2093
P356
P1433
P1476
Improved survival in women with BRCA-associated ovarian carcinoma.
@en
P2093
Beth Y Karlan
Ilana Cass
Rae Lynn Baldwin
Roxana Moslehi
Taz Varkey
P2860
P304
P356
10.1002/CNCR.11310
P407
P577
2003-05-01T00:00:00Z